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rug-Eluting Stents:
afe But Not Sufficient*
obert A. Vogel, MD
altimore, Maryland
rug-eluting stents (DES) were quickly adopted into clin-
cal practice after they were demonstrated to reduce reste-
osis and repeat target lesion revascularization (TLR) com-
ared with bare-metal stents (BMS) (1,2). Concern soon
urfaced over reports of late stent thrombosis with DES (3),
eading to the release of 2 Federal Drug Agency advisories
n 2006. Protracted dual antiplatelet therapy is now advised
fter DES implantation. Differences in antiplatelet therapy
iven to patients receiving DES and BMS complicate the
nterpretation of the relative long-term benefit of stent type.
e are now nearing the end of the DES versus BMS
ebate, with recent studies documenting the safety of
urrent DES (4). Our major concern should now shift back
o the underlying problem beyond the target lesion, namely
rogressive coronary atherosclerosis.
See pages 498 and 504
In this issue of JACC Cardiovascular Interventions, 2
eports categorize the source of late events after DES
lacement. Chacko et al. (5) report 5-year data from the
IRIUS (Sirolimus-Eluting Stent in De Novo Native Cor-
nary Lesions) study, a sirolimus-eluting stent (SES) versus
MS randomized trial in 1,057 subjects at high risk for
estenosis (1). The initial 9-month benefit of SES over
MS in reducing TLR was maintained at 5 years (12.5% vs.
8.8%, p  0.001). No significant differences were observed
etween the SES and BMS cohorts in myocardial infarction
r revascularization at sites within the target vessel remote
rom the target lesion or in nontarget vessels, although a
rend was observed for decreased revascularization with SES
ithin the target vessel remote from the target lesion.
verall death and myocardial infarction were not different
etween the 2 stent cohorts.
Also in this issue, Leon et al. (6) report pooled 5-year
ata from 4 paclitaxel-eluting stent (PES) versus BMS trials
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.p
From the Division of Cardiology, University of Maryland School of Medicine,
altimore, Maryland.f 2,797 subjects with both simple and complex de novo
oronary lesions. The initial reduction in TLR was main-
ained long-term, as with the SES data, and death or myocar-
ial infarction was not different between the PES and BMS
ohorts, although myocardial infarction trended (hazard ratio:
.59, 95% confidence interval: 0.99 to 2.55, p  0.054) more
requent in the PES cohort during years 2 to 5.
It important to document that DES deployment does not
ave remote effects on the coronary vasculature for 2
easons. Restenosis can potentially lead to remote revascu-
arization and hence altered clinical outcome due to in-
reased angiographic surveillance after recurrent symp-
oms. Moreover, in 1987, our group demonstrated that
ngioplasty-induced medial injury but not endothelial de-
udation has adverse vasoactive effects in both the inter-
ened and remote coronary vessels, potentially affecting
therogenesis (7). These effects seem to be mitigated by
ntiplatelet therapy. Similar adverse remote vasoactive ef-
ects have been reported with SES (8).
Although the current studies demonstrate no difference
n remote atherogenesis between DES and BMS placement,
hey cannot evaluate whether either angioplasty or stent
lacement themselves affect remote disease progression. A
econd limitation of the current studies is their failure to
ecord antiplatelet and other medication use during the
xtended follow-up period. Long-term clopidogrel use in
he DES cohorts could have mitigated adverse effects.
nother limitation of the current SES study is its use of a
omposite end point, which included death, myocardial
nfarction, and revascularization. As acknowledged by the
uthors, these end points are not apples and oranges; they
re watermelons and grapes. No number of uneventful
nterventions can be equated with 1 death. Composite end
oints including events in addition to death, myocardial
nfarction, and stroke cloud rather than clarify clinical
esults.
The current reports emphasize that although events
riginating beyond the target lesion occurred equally in the
cohorts they occurred frequently. This finding is consis-
ent with the original observation of Cutlip et al. (9) who
ooled data from 1,228 subjects in 3 second-generation
oronary stent trials over 5 years. After the initial year of
ollow-up, the average annual hazard rate was 1.7% for
vents related to the target lesion but 6.3% for nontarget-
esion vessels. In this study, diabetes mellitus and multives-
el disease were independently associated with increased risk
or remote events. These data underscore the need for
ggressive medical management of all patients undergoing
ny type of percutaneous coronary intervention.
We are probably nearing the end of the DES versus BMS
ebate, at least in terms of clinical safety. Douglas et al. (4)
ecently analyzed the data from 262,700 elderly patients
ndergoing stent placement at 650 sites during a 3-year
eriod beginning in 2004 within the American College of
C
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514ardiology’s National Cardiovascular Data Registry
NCDR). Of these nonrandomized patients, 83% received a
ES and 17% a BMS. Data from the NCDR were linked
o Medicare claims through a unique probabilistic matching
echnique, which resulted in 76% being correctly matched.
fter adjustment for differences in baseline characteristics,
eath and myocardial infarction occurred less frequently in
he DES than in the BMS cohort (hazard ratio: 0.75 and
.77, respectively). Repeat revascularization also occurred
ess frequently in the DES group, although the hazard ratio
as 0.91. Possible incomplete adjustment for group differ-
nces and uncontrolled medication use limit the results from
his very large observational study from certifying the safety
nd efficacy of DES. More valuable information could be
erived from such large databases if our medical information
ystems were less encumbered by excessive concerns for
atient privacy (10).
Ultimately, however, the current study provides no infor-
ation on the relative clinical value of stent placement
ompared with accompanying medical management. To
his end, the COURAGE (Clinical Outcomes Utilizing
evascularization and Aggressive Drug Evaluation) trial
rovides a useful comparison (11). In this trial of optimal
edical management with or without percutaneous coro-
ary intervention, death, myocardial infarction, and other
ajor events occurred at similar rates. In fact, the 4.6-year
ll-cause death or nonfatal myocardial infarction rates were
9.0% and 18.5% for the intervention and nonintervention
roups, respectively, which compare favorably with a 21.0%
ate at 4.8 years for the SES cohort and approximated 17.2%
or the PES cohort in the current studies. This finding is
specially remarkable in view of the fact that DES were not
ntroduced until the final 6 months of the COURAGE
rial. Both the high event rates due to disease remote from
he target lesion in the current study and the excellent
utcomes with aggressive medical management in the
OURAGE trial suggest that the greatest opportunity to
mprove clinical outcomes lies in managing the underlying
therosclerosis. It should be remembered that in the
OURAGE trial optimal medical management in the
nterventional cohort at year 5 had achieved mean values for
lood pressure of 124/70 mm Hg, low-density lipoprotein
holesterol of 71 mg/dl, and glycated hemoglobin of 7.1% in
atients with diabetes mellitus. KInterventions do not cure atherosclerosis, and interven-
ionalists need to be familiar with all the medical details of
ach patient. As an example, I have encountered several
ES-treated patients who were known to require noncar-
iac surgery within months of their intervention, unneces-
arily complicating antiplatelet therapy. A good stent is
ecessary, but having a good physician is even more important.
eprint requests and correspondence: Dr. Robert A. Vogel,
ivision of Cardiology, University of Maryland School of Medi-
ine, 22 South Greene Street, Room S3B06, Baltimore, Maryland
1201. E-mail: rvogel@medicine.umaryland.edu.
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